R.J. Technology INC.

R.J. Technology INC. was paid $1.63M by Medicaid between Jan 2018 and Jan 2020, across 83 billing codes. Its largest line is G0483, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed — 34% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Missouri

Rank by total paid#12 of 61

Median peer was paid$85K

This provider vs. median19×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	51,723	$776K
2019	48,899	$809K
2020	3,006	$46K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	34%	3,853	3,384	$561K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	9.8%	3,742	2,903	$160K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	8.7%	2,271	1,840	$142K
84443	Thyroid stimulating hormone (TSH)	6.0%	7,202	6,662	$97K
80053	Comprehensive metabolic panel	5.3%	10,224	9,377	$86K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	4.2%	3,768	3,486	$69K
80061	Lipid panel	4.2%	8,125	7,534	$69K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	3.3%	1,146	1,043	$53K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	3.3%	9,858	8,883	$53K
83036	Hemoglobin; glycosylated (A1C)	2.0%	5,355	4,955	$33K
82607		1.3%	1,901	1,792	$22K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	1.3%	246	217	$22K

71 more codes

84436		<1%	2,382	$13K
83721		<1%	1,935	$13K
84439		<1%	1,819	$12K
36415	Collection of venous blood by venipuncture	<1%	8,420	$11K
86803		<1%	875	$10K
84153		<1%	735	$10K
82570		<1%	2,429	$10K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	320	$9K
82746		<1%	928	$9K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	317	$9K
86704		<1%	632	$8K
82728		<1%	780	$7K
84479		<1%	1,337	$7K
86038		<1%	702	$7K
80074		<1%	211	$6K
87340		<1%	677	$6K
81001		<1%	2,753	$6K
86708		<1%	644	$6K
80048	Basic metabolic panel (calcium, ionized)	<1%	809	$6K
86317		<1%	555	$5K
85027		<1%	1,010	$5K
86696		<1%	375	$5K
86141		<1%	447	$5K
86705		<1%	405	$5K
82043		<1%	1,203	$4K
83550		<1%	767	$4K
83970		<1%	162	$4K
83540		<1%	949	$4K
84480		<1%	511	$4K
85045		<1%	1,209	$4K
86592		<1%	1,018	$4K
86695		<1%	375	$3K
84481		<1%	408	$3K
84550		<1%	1,000	$3K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	113	$3K
G0103	Prostate cancer screening; prostate specific antigen test (psa)	<1%	222	$3K
86431		<1%	580	$3K
86709		<1%	411	$2K
83735		<1%	522	$2K
87086	Culture, bacterial; quantitative colony count, urine	<1%	304	$2K
85652		<1%	962	$2K
83690		<1%	383	$2K
84146		<1%	98	$1K
82150		<1%	372	$1K
87088		<1%	218	$1K
85610		<1%	448	$1K
80069		<1%	131	$896.19
82248		<1%	231	$866.87
86140		<1%	231	$832.83
83516		<1%	60	$716.40
86800		<1%	74	$700.34
87070		<1%	115	$649.43
86376		<1%	62	$596.29
82378		<1%	34	$580.32
85018		<1%	231	$490.20
87186		<1%	75	$474.10
87071		<1%	65	$457.28
84100		<1%	148	$338.13
84156		<1%	207	$324.82
84403		<1%	13	$313.68
86762		<1%	30	$303.33
82950		<1%	70	$300.56
83001		<1%	16	$287.83
80164		<1%	28	$267.92
85730		<1%	105	$257.76
81003		<1%	190	$222.38
84702		<1%	17	$211.18
80178		<1%	24	$142.00
86706		<1%	16	$137.32
82550		<1%	17	$86.96
81025		<1%	15	$45.13

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialRAZIQ, ABDUL (OWNER)